Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK104 + AK117 + capecitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Kangfang Sainuo Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This combination is an investigational therapeutic regimen comprising four agents for oncology use, primarily in advanced or metastatic solid tumors such as gastric or gastroesophageal junction (GEJ) adenocarcinoma. **AK104 (cadonilimab)** is a bispecific monoclonal antibody targeting both PD-1 and CTLA-4, acting as an immune checkpoint inhibitor to enhance antitumor immunity. **AK117 (ligufalimab)** is a humanized IgG4 monoclonal antibody targeting CD47, blocking the CD47-SIRPα interaction to promote macrophage-mediated phagocytosis of tumor cells without causing hemagglutination. **Capecitabine** is an oral prodrug of 5-fluorouracil (5-FU), inhibiting DNA synthesis as an antimetabolite. **Oxaliplatin** is a platinum-based chemotherapeutic causing DNA crosslinking and apoptosis. Clinical trials of this four-drug combination have reported favorable safety and early efficacy signals in patients with advanced HER2-negative gastric and GEJ cancers[2][4]. AK104 and AK117 are both developed by Akeso.
- Other names
- cadonilimab + ligufalimab + capecitabine + oxaliplatin
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNATS (Thymidylate synthase)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD47 (Cluster of Differentiation 47)
Beyond the preview
Go deeper on AK104 + AK117 + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK104 + AK117 + capecitabine + oxaliplatin.